Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 4/20 | 0.30 |
| ▸ | FAP | Q12884 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25299858 | 1.00 | GABRR1 (0.31) | GABRR1MAPTDPP4FAPDPP7 | |
| SCHEMBL13651247 | 1.00 | GABRR1 (0.31) | GABRR1MAPTDPP4FAPDPP7 | |
| SCHEMBL12491953 | 1.00 | GABRR1 (0.31) | GABRR1MAPTDPP4FAPDPP7 | |
| SCHEMBL18283815 | 0.88 | DPP4 (0.39) | MAPTDPP4FAPDPP7PREP | |
| SCHEMBL8927478 | 0.88 | DPP4 (0.39) | MAPTDPP4FAPDPP7PREP | |
| SCHEMBL4059132 | 0.88 | DPP4 (0.39) | MAPTDPP4FAPDPP7PREP | |
| SCHEMBL22469047 | 0.86 | HPGD (0.40) | DPP4FAPDPP7PREPDPP8 | |
| Hydrochloric Acid SCHEMBL3487428 | 0.86 | DPP4 (0.38) | MAPTDPP4FAPDPP7PREP | |
| SCHEMBL28534805 | 0.78 | RIPK1 (0.44) | DPP4 | |
| SCHEMBL28534808 | 0.78 | RIPK1 (0.44) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220338521-A1 | COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF WEIGHT LOSS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2022-10-27 | — | — | US | disclosed |
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | SALAMA ZOSER B (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | SALAMA ZOSER B (DE) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328051-B2 | Proline or proline derivatives for the treatment of dementia | PSEN2, PSEN1, PRNP | GABRR1 874/4885MAPT 11/4885DPP4 120/4885 |
| US-20170239215-A1 | PROLINE OR PROLINE DERIVATIVES FOR THE TREATMENT OF DEMENTIA | PSEN2, PSEN1, PRNP | GABRR1 874/4885MAPT 11/4885DPP4 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.